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Abstract
Background: Obesity is associated with the development and progression of osteoarthritis (OA). Although the
infrapatellar fat pad (IFP) could be involved in this association, due to its intracapsular localization in the knee
joint, there is currently little known about the effect of obesity on the IFP. Therefore, we investigated cellular
and molecular body mass index (BMI)-related features in the IFP of OA patients.
Methods: Patients with knee OA (N = 155, 68% women, mean age 65 years, mean (SD) BMI 29.9 kg/m2 (5.7)) were
recruited: IFP volume was determined by magnetic resonance imaging in 79 patients with knee OA, while IFPs and
subcutaneous adipose tissue (SCAT) were obtained from 106 patients undergoing arthroplasty. Crown-like structures
(CLS) were determined using immunohistochemical analysis. Adipocyte size was determined by light microscopy and
histological analysis. Stromal vascular fraction (SVF) cells were characterized by flow cytometry.
Results: IFP volume (mean (SD) 23.6 (5.4) mm3) was associated with height, but not with BMI or other obesity-related
features. Likewise, volume and size of IFP adipocytes (mean 271 pl, mean 1933 μm) was not correlated with BMI. Few
CLS were observed in the IFP, with no differences between overweight/obese and lean individuals. Moreover, high BMI
was not associated with higher SVF immune cell numbers in the IFP, nor with changes in their phenotype. No BMI-
associated molecular differences were observed, besides an increase in TNFα expression with high BMI. Macrophages
in the IFP were mostly pro-inflammatory, producing IL-6 and TNFα, but little IL-10. Interestingly, however, CD206 and
CD163 were associated with an anti-inflammatory phenotype, were the most abundantly expressed surface markers on
macrophages (81% and 41%, respectively) and CD163+ macrophages had a more activated and pro-inflammatory
phenotype than their CD163- counterparts.
Conclusions: BMI-related features usually observed in SCAT and visceral adipose tissue could not be detected in the
IFP of OA patients, a fat depot implicated in OA pathogenesis.
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Background
Obesity is associated with the development and pro-
gression of osteoarthritis (OA). This association is not
only observed in weight-bearing joints such as the knee,
but also in hand OA [1, 2]. These observations suggest
that in addition to mechanical factors, systemic factors
associated with obesity play a role in the pathophysi-
ology of OA.
Adipose tissue consists of adipocytes and the stromal
vascular fraction (SVF), which contains a variety of cells,
including immune cells. Obesity is usually accompanied by
adipose tissue inflammation, characterized by changes in
adipocytes and inflammatory cells, leading to a shift from
an anti-inflammatory phenotype to a pro-inflammatory
phenotype of the adipose tissue [3]. Adipocytes are gener-
ally enlarged in obesity and this growth causes expansion
of the adipose tissue, but also adipocyte cell death and
hypoxia [4–6]. This process is accompanied by macro-
phage infiltration and congregation around dead or nec-
rotic adipocytes, resulting in formation of so-called crown
like structures (CLS) where macrophages are thought to
scavenge adipocyte remnants [7–9]. Furthermore, the
polarization state of macrophages in the obese adipose tis-
sue changes towards a more pro-inflammatory phenotype,
thereby sustaining and promoting inflammation of the
adipose tissue [10–12].
The knee joint is characterized by the presence of an
adipose tissue depot called the infrapatellar fat pad (IFP)
also known as Hoffa’s fat pad. The IFP is intracapsularly
and extrasynovially located in close vicinity to the syno-
vium, cartilage and bone. Due to its localization, it is
conceivable that the IFP contributes to the pathophy-
siology of OA in the joint, through secretion of soluble
mediators. Our group and others have shown that the
IFP has a pro-inflammatory phenotype in patients with
advanced knee OA [13–15] and could thereby contri-
bute to inflammation in the joint (reviewed in [16]).
To date, little is known about the effect of obesity on
the IFP. Two magnetic resonance (MR) studies sug-
gested that, unlike subcutaneous tissue, the IFP does not
enlarge with obesity [17, 18]. More recent studies ad-
dressing this question have shown contrasting results in
humans [19, 20], while various body mass index (BMI)-
related changes were observed in the IFP in mice [21].
Moreover, we have previously reported differences in the
IFP, such as enhanced TNFα secretion, in relation to
high BMI [13]. Nonetheless, given the correlation be-
tween obesity and OA, it is important to fully compre-
hend the possible molecular and cellular BMI-related
features in fat tissue located in close contact with the
joints that are affected in OA, as is the case for the IFP.
Therefore, we extensively investigated the cellular and
molecular features of adipose tissue typically associated
with obesity to assess whether the IFP changes in OA
patients with an increase in BMI and could thereby contrib-
ute to disease progression. We determined the association
between high BMI and the volume of the IFP, the volume
of adipocytes, their cytokine secretion profile, and the num-
ber and phenotype of adipose tissue immune cells.
Methods
Human subjects
In total, 155 patients with knee OA were recruited in
the study. The patients were 68% women, with mean age
65 years and mean (SD) BMI 29.9 (5.7) kg/m2. The dis-
tribution of the patients among BMI categories were:
underweight (BMI below 18.5), none; normal (BMI
18.5–24.9), 28 patients; overweight (25.0–29.9), 61 pa-
tients; and obese (30.0 and above), 66 patients. Charac-
teristics of the patients represented in Figs. 1, 2, 3 and 4
are shown in Additional file 1: Table S1. A total of 102
patients were part of the GEneration of Models, Mecha-
nisms & Markers for STratification of OsteoArthritis pa-
tieNts (geMstoan) study, an observational study in
patients with knee OA to find new biomarkers for OA
progression. The patients were included between 2008
and 2014, had symptomatic knee OA, following the
American College of Rheumatology (ACR) criteria [22],
and attended the orthopaedic department of the Leiden
University Medical Centre (LUMC) or the orthopaedic
department of the Alrijne Ziekenhuis in Leiden. Written
informed consent is available from all geMstoan pa-
tients. Of these 102 patients who participated in the
geMstoan study, a total of 79 patients underwent mag-
netic resonance imaging (MRI), 30 of whom underwent
joint-replacement surgery and 49 of whom underwent arth-
roscopy. IFPs and subcutaneous adipose tissue (SCAT)
were obtained from 53 patients participating in geMstoan,
who were undergoing joint replacement surgery after giving
informed consent. Leftover IFP and SCAT were obtained
during arthroplasty from an additional 23 patients from the
LUMC, and 30 patients from Erasmus Medical Centre
(MC). SCAT was obtained from the thigh, next to the inci-
sion made for the total knee-replacement surgery. Diagno-
sis, age, gender and BMI were available for the latter
patients. The study was approved by the local medical eth-
ical committee. Consent was given in accordance with the
guidelines of the Federation of Biomedical Scientific Soci-
eties (http://www.federa.org) after approval by the local eth-
ical committee (MEC 2008-181 and MEC 2012-267). Not
all experiments could be performed with each tissue sample
as the sample size was limited.
MRI acquisition
We used a 3 T Philips Achieva MR system (Philips
Healthcare, Best, The Netherlands) with an 8-channel
dedicated knee coil. Sagittal proton density (PD) fast spin-
echo (FSE)-driven equilibrium images were obtained with
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a field of view (FOV) of 150 × 150 mm, an acquisition
matrix of 304 × 240, slice thickness of 3 mm, repetition
time (TR) of 3000 ms and echo time (TE) of 34 ms. Subse-
quently, contrast enhanced (CE) MR images were ob-
tained following injection of gadoterate meglumine
(0.2 ml/kg) (Dotarem; Guerbet) into the cubital vein using
a power injector (Medrad) with a rate of 2 ml/s followed
by a 40-ml saline flush also at a rate of 2 ml/s. We subse-
quently obtained frequency selective fat-suppressed T1-
weighted, FSE with TR of 655 ms, and TE of 20 ms, in
both the axial and sagittal planes.
IFP volume determination by MRI
IFP volume was measured by manual segmentation of IFP
boundaries on section-by-section sagittal PD FSE images,
using the software program OsiriX. T1-weighted CE
images were used to distinguish and compare between IFP
and non-IFP structures (Additional file 1: Figure S1). The
software program OsiriX measured IFP volume by making
a 3D model of the drawn contours. Two independent ob-
servers measured IFP volume on all MRI scans. The intra-
class correlation (ICC) was 0.957 for intra-observer
reliability (measured in all images). The ICC was 0.909 for
inter-observer reliability (measured in all images).
Measurement of adipocyte size
Adipocytes were isolated as previously described [13].
Briefly, adipose tissue was digested with collagenase type
1A (Sigma-Aldrich) for 1 h and the tissue was filtered
through a 250-μm nylon mesh. Adipocytes were washed
three times with medium (DMEM/F12 supplemented
with 0.5% free fatty acid (FFA) free bovine serum albumin
Fig. 1 Adipocyte volume, and the number of crown-like structures (CLS) and stromal vascular fraction (SVF) cells in the infrapatellar fat pad (IFP) did
not correlate with body mass index (BMI). Adipocytes were isolated from the IFP from patients with osteoarthritis (OA), who were undergoing total
knee-replacement surgery, adipocyte volume was determined and the correlation with BMI was assessed (N = 56) (a). Adipocyte size was determined
upon haematoxylin and eosin (H&E) staining and the correlation with BMI was assessed (N = 18) (b). IFP tissue was stained for CD68 and the number
of CLS was quantified. A representative picture of the staining at × 20 (left) and × 40 (right) magnification (c) and the summary of all results is shown
(N = 11) (d). The number of SVF cells per gram adipose tissue was determined and the correlation with BMI was assessed (N = 39) (e). Correlation was
tested using Spearman’s rank correlation (a, b) or Pearson correlation coefficient (e). Each dot represents one patient. HPF high power field
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Fig. 2 Cell infiltrate in adipose tissue. The stromal vascular fraction (SVF) of the infrapatellar fat pad (IFP) was isolated and T cells and macrophages
were characterized by flow cytometry (gating strategies were performed as described in Additional file 1: Figure S3). Percentages of CD3+ T cells
(N = 21) (a), CD4+ T cells (N = 29) (b), CD8+ T cells (N = 29) (c) and macrophages (N = 37) (d) and their correlation with body mass index (BMI)
was determined using Spearman’s rank correlation. A P value <0.05 was considered significant. Each dot represents one patient





































Fig. 3 Phenotypic characterization of macrophages in the infrapatellar fat pad (IFP). The stromal vascular fraction (SVF) was isolated from the IFP
and macrophages were characterized by flow cytometry. Percentages of CD14+ macrophages positive for each specified marker are depicted (N
= 6–45) (a). Ex vivo intracellular cytokine production by CD14+ macrophages in the IFP is depicted (N = 13) (b). Cytokines were measured in
supernatant of unstimulated CD14+ from the SVF (N = 2) (c). Median (a and b) or mean (c) is indicated; each dot represents one patient. pt patient
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(BSA), 15 mM Hepes, 2 mM glutamax and 100 U/ml peni-
cillin/streptomycin) by allowing them to float to the surface,
followed by removal of medium and addition of fresh
medium. The diameter of 100 adipocytes was determined
with light microscopy with an ocular micrometer and the
mean volume was calculated, based on the formula:
V = πd3/6,
where d is the diameter of the adipocyte, and the mean
volume of adipocytes was then calculated. Explants of
the IFP and SCAT were also cryosectioned and stained
with haematoxylin and eosin (H&E) and imaged using
an Olympus SC30 camera (Olympus, Zoeterwoude, The
Netherlands). The cross-sectional area of the imaged
adipocytes was calculated using Fiji Is Just ImageJ soft-
ware with the additional Adiposoft plugin. Three separ-
ate sections, with a minimum of 25 adipocytes in each
section were measured per donor. The Adiposoft appli-
cation was calibrated to identify cells with a diameter be-
tween 30 and 130 μm. A 0.33 μm/pixel measuring-scale
was also used by the application to determine the cross-
sectional area (size) of each adipocyte identified in the
images. A manual inspection of output data was per-
formed to confirm the consistency of the measurements.
Histological staining
Pieces of IFP were fixed in 4% formalin overnight
followed by storage in EtOH, before embedding in
Fig. 4 CD163+ macrophages in the infrapatellar fat pad (IFP) are pro-inflammatory. Total macrophage population (left), and CD163+ (red) and
CD163- CD14+ (green) macrophages (right) are depicted against the forward scatter-area (FSC-a) (a). Differences between CD163+ and CD163-
CD14+ macrophages in surface marker expression (N = 7–12) (b) and ex vivo intracellular cytokine production (N = 7–8) (c). Each line indicates one
patient sample. A P value <0.05, determined by the Wilcoxon signed rank test (b) or paired Student’s t test (c) was considered significant
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paraffin. Sections of 4 μm at different depths in the tis-
sue were deparaffinised in xylene (Merck, Germany)
and EtOH. Endogenous antigens were peroxidised in a
MetOH/H2O2 solution, and antigen retrieval was per-
formed with EDTA (DAKO, USA) at 96 °C for 30 min.
After cooling, two consecutive coupes of three different
layers were stained for mouse anti-human CD68 (clone
KP-1 1:800, DAKO, USA) or the isotype control
(mIgG1 (DAKO, USA)) for 1 h at room temperature
(RT). CD68+ cells were then visualized using DAKO
EnVision and DAB Ni kits, according to manufac-
turers’ instructions (DAKO, USA; Vector Laboratories,
Canada) before counterstaining with haematoxylin
(Klinipath, The Netherlands). Slides were then embed-
ded in pertex (Histolab Products, Sweden) and ana-
lysed using a Leica microscope and Leica software.
Two to three slides per patient were used and a total
of 11–37 high power field (HPF) pictures were taken
depending on the size of the tissue. Two independent
scorers (AJJ and SNA) quantified the amount of CLS
(the ICC for inter-observer reliability was 0.985) in
each HPF and an average of both scorers was gener-
ated for the amount of CLS per HPF.
SVF isolation
The stromal vascular fraction (SVF) was isolated from
the IFP and SCAT as previously described [13]. SVF cells
were counted by light microscopy, surface staining was
performed and the remaining cells were plated overnight
in a 6-well plate at a density of maximal 5 × 106 cells/
well in medium (DMEM/F12 supplemented with 0.5%
FFA free BSA, 15 mM Hepes, 2 mM glutamax and 100
U/ml penicillin/streptomycin) supplemented with 50 IU/
ml IL-2 (Peprotech, USA) and 3 μg/ml Brefeldin A
(Sigma Aldrich, Germany). Thereafter, cells were har-
vested using a cell scraper and surface and intracellular
staining was performed. The SVF of the IFP from two
patients was used to isolate CD14+ cells using magnetic-
labelled anti-CD14 beads (Miltenyi Biotec) according to
the manufacturer’s instructions. CD14+ cells were plated
in a 96-well plate and supernatant was harvested after
2 days of culture.
Flow cytometric analysis
Approximately 100,000 freshly isolated SVF cells were
stained for 30 min at 4 °C with surface antibody (Ab) solu-
tions containing mixes of the following Abs: PE-
conjugated CD1d, CD3, DC-SIGN, CD206 and CD16;
FITC-conjugated HLA-DR, CD11c and CD45; APC-
conjugated CD8 and CD163; PE-Cy-7-conjugated CD14,
PB-conjugated CD4 and Pe-Cy5-conjugated CD206 (all
Abs from BD biosciences, except Ab to CD163 and
CD206, which were from Biolegend). When specified, ap-
proximately 400,000 SVF cells harvested after overnight
incubation with brefeldin A were stained for 30 min at 4 °C
for surface markers and intracellular cytokines using the
BD intracellular cytokine fixation/permeabilization solution
kit (BD Biosciences) according to the manufacturer’s
instructions. The following Abs were used: PE-Cy7-
conjugated CD14; APC-conjugated CD163; PE-conjugated
IL-10, TNFα and IL-6 (all Abs from BD biosciences, except
Ab to IL-6 which was from eBioscience). Exclusion of dead
cells was performed in all experiments using the Dead Cell
discrimination kit (Miltenyi Biotec, Germany). Cells were
fixed with 1% paraformaldehyde and analysed with a LSR II
flow cytometer using Diva 6 software (BD biosciences).
Generation of fat-conditioned and adipocyte-conditioned
medium
Fat-conditioned and adipocyte-conditioned medium (FCM
and ACM, respectively) were obtained as previously de-
scribed [13]. Briefly, FCM was obtained by culturing
100 mg/ml of small pieces of IFP or SCAT in 6-well plates
in medium (DMEM/F12 supplemented with 0.5% FFA free
BSA, 15 mM Hepes, 2 mM glutamax and 100 U/ml peni-
cillin/streptomycin). Medium was refreshed after 2 h and
supernatant was collected after 24 h. For ACM, 100 μl/ml
of adipocytes were cultured in 6-well plates in medium for
24 h. Supernatants were collected and stored at −80 °C
until use.
Milliplex MAP analysis
Cytokines were measured in supernatants of CD14+ cells
isolated from SVF and in FCM and ACM using the
Milliplex Human Cytokine/Chemokine kit (Millipore),
the Bio-Plex array reader and Bio-Plex software in ac-
cordance with the manufacturer’s instructions.
Statistical analysis
Associations between IFP volume measured by MRI and
patient characteristics were determined by linear regres-
sion analysis after establishing that the assumptions
underlying linear regression analysis were met. Both uni-
variate and multivariate linear regression analyses were
performed to determine which patient characteristics
were associated with IFP volume. The unpaired or
paired Student’s t test (for normally distributed variables)
or the Mann-Whitney test or Wilcoxon’s matched-pairs
signed rank test (for non-Gaussian distributions) was
used to compare differences between groups. Correlation
was tested by calculating the Pearson correlation coeffi-
cient (for normally distributed variables) or by using
Spearman’s ranked correlation test (for non-Gaussian
distributions), as specified. For Pearson correlation, the
trend line with 95% confidence interval was depicted.
Correction for multiple testing was performed using
Bonferroni’s correction. A P value ≤0.05 was considered
statistically significant.
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Results
IFP volume is associated with gender and height but not
with BMI
To obtain insight into whether the volume of the IFP is as-
sociated with obesity-related features or other patient char-
acteristics, we made use of a clinically well-characterized
population of patients participating in the geMstoan study
(N = 79). Patient characteristics are shown in Table 1. The
mean (SD) IFP volume was 23.6 (5.4) mm3. Univariate lin-
ear regression analysis indicated that BMI is not associated
with IFP volume (Table 2). Other obesity-related features
such as waist-to-hip ratio (R2 = 0.09) and fat percentage
(R2 = 0.19) were associated with IFP volume, while waist
circumference was not. Moreover, IFP volume was associ-
ated with male gender (R2 = 0.37), height (R2 = 0.47) and
weight (R2 = 0.07), but not with age, nor with radiographic
damage (Kellgren-Lawrence (KL) scores) (Table 2). Multi-
variate linear regression analysis in which all factors that
were significantly associated with IFP volume were in-
cluded indicated that only height remained independently
associated with IFP volume (Table 2). The association with
gender was still present, but was no longer significant. To
understand how the factors included in the multivariate
analysis vary with height and gender, we included height or
gender as covariates in the linear regression analysis. These
analyses indicate that gender is a confounder for most of
the observed associations and that only height remained
significantly associated with IFP volume upon correction
for gender (Table 2). Stratification based on gender indi-
cated that height is associated with IFP volume in women
but not in men (data not shown). Of all patients,
17.9% had cardiovascular comorbidities, indicating the
presence of metabolic complications. There was no
association between IFP volume and BMI upon strati-
fication for the presence of these comorbidities (data
not shown).
Adipocyte volume, and the number of CLS and SVF cells
in the IFP did not correlate with BMI
Next, we investigated adipocytes and SVF cells in the
IFP. The average volume of adipocytes was 271 pl
(Fig. 1a), and the average size was 1933 μm (Fig. 1b).
Neither the volume nor the size of adipocytes correlated
with BMI. Furthermore, the distribution of adipocyte
sizes was not different between lean and obese individ-
uals. Macrophage staining indicated that CLS (Fig. 1c)
were present in small numbers in the IFP (mean = 0.18
CLS/HPF) and did not correlate with BMI (Fig. 1d).
Likewise, the number of SVF cells in the IFP did not cor-
relate with BMI (Fig. 1e). In contrast, we did observe
BMI-related differences in adipocyte volume (Additional
file 1: Figure S2a) and size (Additional file 1: Figure S2b-
c), and the number of SVF cells (Additional file 1: Figure
S2d) in SCAT, a control adipose tissue. Direct compari-
son between the IFP and SCAT revealed that IFP adipo-
cytes are smaller compared to SCAT adipocytes
(Additional file 1: Figure S2e-f ), but IFP has more SVF
cells compared to SCAT (Additional file 1: Figure S2g).
Cell infiltrate in adipose tissue
Next, we investigated the type of immune cells in the
IFP. Therefore, we determined the percentage of macro-
phages and T cells in the SVF from the IFP, since these
cell types are the most abundant immune cells in adi-
pose tissue. Our data indicated that there was no correl-
ation between CD3+ T cells (Fig. 2a), CD4+ T cells
(Fig. 2b), CD8+ T cells (Fig. 2c) or macrophages (Fig. 2d)
and BMI, suggesting no BMI-related differences in the
types of immune cells in the IFP.
Previously, we found that TNFα secretion by FCM but
not ACM correlated with BMI [13]. Using a different co-
hort of patients, we now showed that FCM derived from
the IFP of patients with a high BMI (BMI >30) had
higher levels of TNFα compared to FCM derived from
the IFP of patients with a low BMI (BMI ≤25), confirm-
ing our previous data (Additional file 1: Table S2). In line
with our previous findings, levels of TNFα in ACM did
not differ between these high and low BMI groups (Add-
itional file 1: Table S2). We further expanded our ana-
lyses to a broad range of cytokines. These studies
indicated that several cytokines, such as interferon
(IFN)α, IL-2, IL-3, IL-4, IL-5, IL-9, IL-13, IL-15, IL-17,
platelet-derived growth factor (PDGF)-ABBB, sCD40L,
transforming growth factor (TGF)α and TNFβ were un-
detectable in most FCM and ACM samples. Moreover,
FCM had higher levels of granulocyte macrophage-
colony stimulating factor (GM-CSF), IL-8 and monocyte
chemotactic protein 3 (MCP3) in the group with BMI
>30 compared to the group with BMI ≤25 (Additional
file 1: Table S3). Likewise, although ACM contained very
low levels of TGFα, these seemed to be lower in the
Table 1 Characteristics of patients (N = 79) in whom infrapatellar
fat pad volume was measured
Parameters Value
Age, year, mean (SD) 62.1 (7.5)
Female, N (%) 54 (68.4)
BMI, kg/m2, mean (SD) 29.4 (5.2)
Height, cm, mean (SD) 170 (9.0)
Weight, kg (SD) 85 (16.4)
Kellgren and Lawrence grade, N (%)a
Grade 1 11 (14.1)
Grade 2 21 (26.9)
Grade 3 25 (32.1)
Grade 4 21 (26.9)
BMI body mass index
aN = 78 patients included in the analysis of Kellgren and Lawrence grade
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group with BMI >30 compared to the group with BMI
≤25 (Additional file 1: Table S4). These differences, how-
ever, were no longer significant after correction for mul-
tiple testing.
Phenotypic characterization of macrophages in the IFP
Because macrophages are abundant in the adipose tissue
and their phenotype has been shown to change with obes-
ity, we investigated the phenotype of macrophages in the
IFP. Virtually all macrophages expressed human leukocyte
antigen (HLA)-DR, while CD1c, CD1d, CD11c and DC-
SIGN were present on a low percentage of cells (Fig. 3a).
Furthermore, among the surface molecules associated
with a pro-inflammatory macrophage phenotype, CD16
was the most abundantly expressed, being present on
approx. 20% of macrophages, while 80% of the macro-
phages expressed the mannose receptor CD206, a surface
molecule associated with an anti-inflammatory phenotype.
Furthermore, less than half of the macrophages expressed
the scavenger receptor CD163. None of the surface
markers correlated with BMI.
Intracellular cytokine staining revealed that macro-
phages from the IFP produced mainly IL-6 and TNFα,
but little IL-10 directly ex vivo (Fig. 3b), indicating a pre-
dominantly pro-inflammatory phenotype. No correlation
with BMI was observed for any of these cytokines (data
not shown). The intracellular cytokine findings were
confirmed in culture supernatants of isolated macro-
phages from two patients (Fig. 3d). Furthermore, these
analyses revealed that CD14+ cells from the IFP were
also capable of secreting eotaxin, fibroblast growth
factor-2 (FGF-2), Flt3-ligand, fractalkine, growth-
regulated oncogene (GRO), granulocyte colony stimulat-
ing factor (G-CSF), GM-CSF, IFNα2, IFNγ, IL-1α, IL-1β,
IL-1RA, IL-7, IL-8, IL-12p40, IP-10, MCP-1, MCP-3,
MDC, macrophage inflammatory protein (MIP)1α,
MIP1β, RANTES, sCD40L, sIL-2Rα, TNFβ and vascular
endothelial growth factor (VEGF) (data not shown).
CD163+ macrophages in the IFP are pro-inflammatory
Surface marker expression indicated an anti-inflammatory
phenotype of IFP macrophages, while the cytokine pro-
duction profile suggests that pro-inflammatory macro-
phages are predominant. However, a restricted percentage
of macrophages secrete IL-10, indicating them as anti-
inflammatory. The scavenger receptor CD163 has been
associated with the resolution of inflammation and tissue
regeneration [23–25], but also with inflammation [26–31].
This indicates that the phenotype of CD163+ macrophages
is unclear. Therefore, we set out to investigate whether
the CD163+ macrophages comprise the anti-inflammatory
macrophage population and compared them to their
CD163- counterparts. Flow cytometric characterization in-
dicated that CD163+ macrophages are bigger than their
CD163- counterparts (Fig. 4a). Furthermore, we found
that the percentages of cells positive for CD16, CD206,
DC-SIGN and HLA-DR were higher, while the percentage
of cells positive for CD1d was lower in CD163+ macro-
phages compared to their CD163- counterparts (Fig. 4b).
Additionally, CD163+ macrophages were more often
positive for IL-6 and TNFα than for IL-10 and seemed to
be more positive for TNFα than CD163- macrophages
(Fig. 4c). These data indicate that although CD163 is
regarded as an anti-inflammatory macrophage marker,
CD163+ macrophages from the IFP display a pro-
inflammatory phenotype.
Discussion
In this study, we investigated cellular and molecular BMI-
related features in the IFPs from OA patients. Our data in-
dicate no substantial differences in the volume of the IFP,
adipocyte size or in immune cell numbers and types in re-
lation according to BMI. These data are important as they
indicate differential regulation of BMI-related features in
different fat tissues. Molecularly, we confirmed the previ-
ously reported increase in TNFα secretion in the high-BMI
group, but did not find additional significant differences in
Table 2 Association between patient characteristics and IFP size measured on MRI
Variable Univariate Multivariate Covariate height Covariate gender
B (95% CI) P value B (95% CI) P value B (95% CI) P value B (95% CI) P value
Age -0.07 (-0.2; 0.1) 0.417 0.06 (-0.1; 0.2) 0.369 -0.08 (-0.2; 0.06) 0.258
Gender 6.93 (4.8; 9.0) <0.001 4.24 (-0.8; 9.3) 0.098 3.33 (0.9; 5.7) 0.006
BMI -0.14 (-0.4; 0.1) 0.258 -0.05 (-0.2; 0.1) 0.560 -0.06 (-0.2; 0.1) 0.549
Waist-to-hip ratio 19.8 (5.9; 33.7) 0.006 -6.32 (-20.4; 7.7) 0.373 4.72 (-6.7; 16.1) 0.412 -9.5 (-24.7; 5.9) 0.222
Waist circumference 0.04 (-0.06; 0.1) 0.391 0.003 (-0.1; 0.1) 0.932 -0.02 (-0.1; 0.06) 0.682
Fat percentage -0.29 (-0.4; -0.2) <0.001 0.01 (-0.3; 0.3) 0.943 -0.13 (-0.3; -0.1) 0.024 0.02 (-0.2; 0.2) 0.824
Height 0.41 (0.3; 0.5) <0.001 0.31 (0.2; 0.4) <0.001 0.29 (0.2; 0.4) <0.001
Weight 0.08 (0.01; 0.2) 0.023 -0.02 (-0.1; 0.1) 0.773 -0.02 (-0.1; 0.1) 0.475 0.04 (-0.02; 0.1) 0.207
KL score 0.28 (-0.9; 1.5) 0.648 -0.29 (-1.2; 0.6) 0.523 -0.5 (-1.5; 0.5) 0.291
IFP infrapatellar fat pad, MRI magnetic resonance imaging, BMI body mass index, KL Kellgren and Lawrence
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other cytokines tested. Extensive characterization of mac-
rophages present in the IFP indicated that most cells bear
surface markers associated with an anti-inflammatory
phenotype (CD206 and CD163), while they secrete pre-
dominantly pro-inflammatory cytokines (TNFα and IL-6).
Comparisons between CD163+ and CD163- macrophages
in the IFP indicated that CD163+ are pro-inflammatory,
larger and more activated than CD163- macrophages.
A high BMI does not necessarily reflect obesity; how-
ever, in our geMstoan population, waist circumference
and fat percentage both correlated well with BMI (data
not shown), indicating that high BMI does reflect obesity
in this population of patients. Furthermore, the presence
of cardiovascular comorbidities in the obese is higher as
compared to lean individuals indicating a high BMI is
accompanied by metabolic complications in our popula-
tion. Although we cannot formally assess this for the
other patients included in this study, they are compar-
able to the geMstoan patients (age above 50 years, all di-
agnosed with OA), suggesting that a high BMI in these
patients also reflects obesity rather than high muscle
content.
Our finding that IFP volume determined by MRI is
not associated with BMI is in line with previous pub-
lished data [17, 18]. Other obesity-related factors such as
waist-to-hip ratio, fat percentage, weight and the pres-
ence of cardiovascular comorbidities were not associated
with IFP volume, were no longer significant in the multi-
variate analysis or when corrected only for gender (data
not shown), in line with known gender differences in
these obesity-related features [32]. Together, these data
support our conclusion that IFP volume is not associ-
ated with obesity.
In contrast, we found that height and gender are asso-
ciated with IFP volume, in agreement with previous
studies [18, 33–35]. Multivariate analysis indicated, how-
ever, that only height is independently associated with
IFP volume, while the association with gender is partially
explained by height, leading to a strongly diminished ef-
fect size when compared to univariate analysis. More-
over, the association was no longer significant, possibly
reflecting a lack of sufficient power. Furthermore, strati-
fication based on gender indicated that height is only
associated with IFP volume in women. Although the
mechanisms underlying the association between gender
and IFP volume remain unknown, it is conceivable that
sex hormones could play a role in this as they have been
previously described to direct fat storage to different
anatomical locations [36]. In contrast to a previous study
[17], we did not find an association between IFP volume
and age, possibly due to differences in the investigated
OA populations, and in the analyses performed.
Previously published data indicate that obesity is ac-
companied by enlargement of adipocytes [5, 6] and
inflammatory cell infiltration in conventional adipose tis-
sues [12, 37, 38]. However, these BMI-related features
do not seem to be present in the IFP, although we ob-
served these features in SCAT. Moreover, we did not
find an association between any type of inflammatory
cells and BMI. However, due to the small sample size
available for CD3+ T cells the power of this analysis is
limited and the lack of association should be interpreted
with care. Although a recent study indicated that
obesity-related changes such as in adipocyte size and
cellular infiltrate occur in the IFP [19], our observations
are in line with other studies indicating that the IFP is
not enlarged in obesity [17] and does not have obesity-
related features [20], supporting earlier findings that the
IFP is different from SCAT [13, 20].
The lack of enlargement in the IFP with obesity could
be due to its localization inside the knee capsule, which
could strongly limit its growth. The question remains,
however, as to how the IFP deals with the metabolic
stress (i.e. nutrient overload) that accompanies obesity.
One could speculate that IFP adipocytes are less meta-
bolically active and are rather inefficient in removing
free fatty acids from the circulation and storing them in
lipid droplets. Therefore, IFP adipocytes, unlike adipo-
cytes in other adipose tissues, are not enlarged with
obesity. Moreover, this could explain the very small
number of CLS and the lack of BMI-related increase in
inflammatory cells in the IFP, as IFP adipocytes might
undergo less apoptosis/cell death, which are the primary
events in adipose tissue inflammation. However, this re-
mains to be investigated. Moreover, our data are relevant
as they indicate that understanding of the biology of fat
tissue located in close contact with joints affected by OA
is important to better comprehend the association be-
tween obesity and OA, but caution should be taken in
translating findings observed in fat tissues to the IFP, a
fat tissue implicated in OA pathogenesis.
Our data indicated that macrophages from the IFP
have a dual phenotype, with surface markers associ-
ated with an anti-inflammatory phenotype and more
pro-inflammatory cytokine profiles. Almost all IFP
macrophages expressed CD206, a marker generally
associated with M2-like macrophages and tissue-
resident macrophages. The phenotype and function of
CD163+ macrophages is unclear, as CD163+ macro-
phages have been associated with wound healing and
the resolution of inflammation [23–25], but have also
been implicated in inflammation, such as in spondy-
loarthritis [26–29], psoriasis [29, 30] and inflamma-
tory bowel disease [27, 31]. Our data are in line with
previous publications showing that macrophages from
SC and omental adipose tissue express both CD163
and CD206 and display a pro-inflammatory cytokine
profile [39].
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Studies in mice suggest that obese adipose tissue be-
comes infiltrated with macrophages, which form CLS,
take up lipids and acquire a more pro-inflammatory
phenotype [40, 41]. In the IFP, CD163+ macrophages ap-
peared to have a more activated state compared to
CD163- macrophages and were larger than CD163- mac-
rophages. This could indicate that CD163+ macrophages
are scavenging dead adipocytes, thereby acquiring more
lipids. Supporting our hypothesis, a recent study in mice
showed that phagocytosis by macrophages leads to up-
regulation of both CD206 and CD163 [42].
We did not observe obesity-related differences in
TNFα production by macrophages (data not shown).
This is surprising in view of the finding that the IFP in
obese individuals secretes more TNFα [13] and that
macrophages are the most abundant cell type in the
SVF. Differences in the regulation of secretion vs pro-
duction could explain the discrepancy. Alternatively, it is
possible that other cells, albeit less numerous, would
secrete more TNFα than macrophages [43] and this se-
cretion could be modulated by obesity. Finally, it is pos-
sible that dissociation of cells from the tissue could
influence their cytokine production.
Conclusions
In conclusion, no cellular BMI-related features previ-
ously reported in other adipose tissues were found in the
IFPs of OA patients with regard to the IFP volume, adi-
pocyte volume and size, CLS, immune cell numbers or
type. These data confirm our previous findings that the
IFP is different to SCAT and raise the intriguing possibil-
ity that the IFP might be a different type of fat than the
conventional SCAT and visceral adipose tissues.
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